We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

135 hedge funds and large institutions have $1.1B invested in Viridian Therapeutics in 2023 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 54 increasing their positions, 37 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

246% more call options, than puts

Call options by funds: $7.59M | Put options by funds: $2.19M

87% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 15

46% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 37

11% more funds holding

Funds holding: 122 → 135 (+13)

2.05% less ownership

Funds ownership: 102.45% → 100.39% (-2.1%)

9% less capital invested

Capital invested by funds: $1.21B → $1.1B (-$110M)

36% less funds holding in top 10

Funds holding in top 10: 11 → 7 (-4)

Holders
135
Holders Change
+13
Holders Change %
+10.66%
% of All Funds
2.15%
Holding in Top 10
7
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-36.36%
% of All Funds
0.11%
New
28
Increased
54
Reduced
37
Closed
15
Calls
$7.59M
Puts
$2.19M
Net Calls
+$5.4M
Net Calls Change
+$5.51M

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$36.2M
2
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$33.4M
3
HRCM
Hood River Capital Management
Florida
+$18.2M
4
PCH
Polar Capital Holdings
United Kingdom
+$17.6M
5
State Street
State Street
Massachusetts
+$17.3M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$35.9M
2
BI
BVF Inc
California
-$34.3M
3
DTC
Deep Track Capital
Connecticut
-$17.3M
4
KCM
Kynam Capital Management
New Jersey
-$15.7M
5
TCM
TCG Crossover Management
California
-$10.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
SO
126
STRS Ohio
Ohio
$20K +$25.7K +800 New
QT
127
Quantbot Technologies
New York
$17.8K +$22.4K +700 New
Nisa Investment Advisors
128
Nisa Investment Advisors
Missouri
$16K +$19.9K +620 +2,480%
Simplex Trading
129
Simplex Trading
Illinois
$14K -$144K -4,502 -89%
LC
130
Lindbrook Capital
California
$3.97K +$5K +156 New
TWA
131
TCI Wealth Advisors
Arizona
$3.36K +$4.23K +132 New
CHA
132
Carmichael Hill & Associates
Maryland
$1.02K – – –
IFAM
133
Institutional & Family Asset Management
Colorado
$254 +$321 +10 New
EI
134
Ellevest Inc
New York
$229 +$289 +9 New
D.E. Shaw & Co
135
D.E. Shaw & Co
New York
– -$9.88M -338,167 Closed
B
136
Braidwell
Connecticut
– -$9.15M -313,403 Closed
Balyasny Asset Management
137
Balyasny Asset Management
Illinois
– -$8.9M -304,552 Closed
Ameriprise
138
Ameriprise
Minnesota
– -$7.82M -267,765 Closed
PAMP
139
Polar Asset Management Partners
Ontario, Canada
– -$5.98M -204,600 Closed
MCM
140
Moore Capital Management
New York
– -$4.09M -140,000 Closed
TI
141
Trexquant Investment
Connecticut
– -$1.05M -35,887 Closed
PVI
142
Pura Vida Investments
New York
– -$1.02M -35,003 Closed
SSA
143
Schonfeld Strategic Advisors
New York
– -$917K -31,400 Closed
BC
144
Brookfield Corp
Ontario, Canada
– -$815K -27,915 Closed
MFS
145
Mirabella Financial Services
United Kingdom
– -$753K -25,769 Closed
CANY
146
Caxton Associates (New York)
New York
– -$525K -17,974 Closed
Squarepoint
147
Squarepoint
New York
– -$503K -17,207 Closed
KI
148
Kula Investments
Illinois
– -$309K -10,580 Closed
GTCM
149
Gyon Technologies Capital Management
New Jersey
– -$236K -8,086 Closed
C
150
Covestor
United Kingdom
– +$96 +3 New
2 3 4 5
6

VRDN Hedge Fund Activity: Q1 2023 in Review

135 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q1 2023, worth a combined $1.1B — down 9.1% from $1.21B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new VRDN positions and 15 closed out — a net gain of 13 holders — while 54 added to existing stakes and 37 trimmed.

The largest buyer was RA Capital Management, adding an estimated $36.2M. The largest seller was Citadel Advisors, cutting an estimated $35.9M.

  • 135 institutional investors held Viridian Therapeutics (VRDN) as of Q1 2023, up from 122 in Q4 2022.
  • Funds reported $1.1B of Viridian Therapeutics stock for Q1 2023, down 9.1% quarter-over-quarter.
  • 28 funds opened new Viridian Therapeutics positions in Q1 2023 and 15 closed out, a net change of +13 holders.
  • The largest Viridian Therapeutics buyer in Q1 2023 was RA Capital Management, an estimated $36.2M added.
  • The largest Viridian Therapeutics seller in Q1 2023 was Citadel Advisors, an estimated $35.9M sold.

Based on aggregated 13F filings for Q1 2023.